Phase 3 trial of Descartes-08 in treating MG may launch in 2025
Cartesian Therapeutics is planning to launch a pivotal, Phase 3 clinical trial of its experimental cell therapy…
Articles by Marisa Wexler, MS
Model may predict gMG disease symptoms’ response to treatment
A machine learning model taking into account markers of inflammation and clinical data may accurately predict whether people with…
Soliris effective for myasthenic crisis in 4 patients in China
Treatment with Soliris (eculizumab) was effective for managing myasthenic crisis in four people with myasthenia gravis (MG) at…
Study links hard-to-manage gMG disease symptoms to higher costs
People with generalized myasthenia gravis (gMG) with many hospital visits before diagnosis or hard-to-manage disease symptoms at the…
Myasthenia gravis ‘unpredictable’ during pregnancy, case study shows
The case of a pregnant woman with myasthenia gravis (MG) who saw her disease worsen and who developed hydramnios…
Acupuncture, moxibustion may relieve myasthenia gravis symptoms
A traditional Chinese medicine practice that combines acupuncture and moxibustion, given along with standard treatments, may ease symptoms for people…
Vyvgart may benefit gMG patients regardless of antibody status
Vyvgart (efgartigimod) eased symptoms of generalized myasthenia gravis (gMG) for some patients in Japan and the therapy’s effects…
Asthma therapy may help ease symptoms of MuSK-positive MG
Treatment with an oral version of salbutamol, the active ingredient of medications used for asthma and other respiratory conditions, may…
Dianthus launches Phase 2 trial to test DNTH103 in generalized MG
Dianthus Therapeutics is launching a Phase 2 clinical trial to test its experimental therapy, DNTH103, in people with…
Use of under-the-skin efgartigimod now approved for gMG in Japan
An under-the-skin or subcutaneous injection formulation of efgartigimod has been approved in Japan for use by adults with generalized…